IRS-4 Inhibitors
IRS-4 inhibitors encompass a range of chemicals that either directly or indirectly modulate the activity of Insulin Receptor Substrate 4 (IRS-4) by targeting specific signaling pathways. Wortmannin and LY294002 directly inhibit IRS-4 by targeting the PI3K pathway, disrupting downstream signaling cascades and attenuating phosphorylation. Rapamycin indirectly influences IRS-4 through mTOR inhibition, altering phosphorylation and activation. MK-2206 directly inhibits IRS-4 by targeting the AKT pathway, disrupting downstream signaling and interfering with IRS-4 activation.
BAY-61-3606 indirectly influences IRS-4 through Syk inhibition, impacting the JAK/STAT pathway. U0126 and SB202190 directly inhibit IRS-4 by targeting the MAPK/ERK and p38 MAPK pathways, respectively. BMS-345541 indirectly modulates IRS-4 through IKK inhibition, affecting the NF-κB pathway. TGX-221 directly inhibits IRS-4 by targeting the PI3K pathway, disrupting downstream signaling cascades. JNK Inhibitor VIII directly influences IRS-4 by inhibiting the JNK pathway. AG-1024 directly inhibits IRS-4 by targeting the IGF-1R pathway, disrupting downstream signaling and interfering with IRS-4 activation. BAY 11-7082 indirectly influences IRS-4 through NF-κB inhibition, altering phosphorylation and activation. These inhibitors provide valuable tools for dissecting the intricate signaling networks involving IRS-4, offering insights into its regulatory mechanisms.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3-kinase inhibitor, directly targets the PI3K pathway. By inhibiting PI3K, Wortmannin disrupts the downstream signaling cascade that includes IRS-4. This interference can lead to decreased phosphorylation of IRS-4 and attenuate its activation, acting as a direct inhibitor of IRS-4. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3-kinase inhibitor that hinders the PI3K pathway. Its inhibition of PI3K disrupts the signaling cascade involving IRS-4, leading to diminished phosphorylation and activation of IRS-4. The direct interference with PI3K, a crucial upstream regulator of IRS-4, classifies LY294002 as a direct inhibitor of IRS-4. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly influences IRS-4 by targeting the mTOR pathway. Inhibition of mTOR by Rapamycin disrupts the downstream signaling pathways that involve IRS-4. The indirect modulation of IRS-4 through mTOR inhibition can result in altered phosphorylation and activation of IRS-4, acting as an indirect inhibitor of IRS-4. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
MK-2206, an AKT inhibitor, directly targets the AKT pathway. By inhibiting AKT, MK-2206 interferes with the downstream signaling pathways that involve IRS-4. This direct inhibition disrupts the phosphorylation and activation of IRS-4, categorizing MK-2206 as a direct inhibitor of IRS-4. | ||||||
BAY 61-3606 | sc-507485 | 2 mg | $345.00 | 1 | ||
BAY-61-3606 is a Syk inhibitor that influences IRS-4 indirectly by impacting the JAK/STAT pathway. Through Syk inhibition, BAY-61-3606 can modulate the downstream signaling cascades, including JAK/STAT, which are connected to IRS-4. This indirect modulation can result in altered phosphorylation and activation of IRS-4, categorizing BAY-61-3606 as an indirect inhibitor of IRS-4. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB202190 is a p38 MAPK inhibitor that directly influences the MAPK pathway. By inhibiting p38 MAPK, SB202190 disrupts the downstream signaling pathways involving IRS-4. The direct inhibition interferes with the phosphorylation and activation of IRS-4, categorizing SB202190 as a direct inhibitor of IRS-4. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $312.00 | 1 | |
BMS-345541 is an IKK inhibitor that indirectly influences IRS-4 through the NF-κB pathway. By inhibiting IKK, BMS-345541 modulates the downstream signaling cascades connected to IRS-4. This indirect modulation can result in altered phosphorylation and activation of IRS-4, categorizing BMS-345541 as an indirect inhibitor of IRS-4. | ||||||
PI 3-Kβ Inhibitor VI, TGX-221 | 663619-89-4 | sc-203190 | 1 mg | $437.00 | ||
TGX-221, a PI3Kβ inhibitor, directly targets the PI3K pathway. By inhibiting PI3Kβ, TGX-221 disrupts the downstream signaling cascades involving IRS-4. The direct inhibition interferes with the phosphorylation and activation of IRS-4, classifying TGX-221 as a direct inhibitor of IRS-4. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $272.00 | 2 | |
JNK Inhibitor VIII is a JNK inhibitor that directly influences the JNK pathway. By inhibiting JNK, this compound disrupts the downstream signaling cascades involving IRS-4. The direct inhibition interferes with the phosphorylation and activation of IRS-4, categorizing JNK Inhibitor VIII as a direct inhibitor of IRS-4. | ||||||
AG 1024 | 65678-07-1 | sc-205907 | 1 mg | $107.00 | 22 | |
AG-1024, a tyrosine kinase inhibitor, directly targets the IGF-1R pathway. By inhibiting IGF-1R, AG-1024 disrupts the downstream signaling cascades involving IRS-4. The direct inhibition interferes with the phosphorylation and activation of IRS-4, classifying AG-1024 as a direct inhibitor of IRS-4. | ||||||